Key result
Class I antiarrhythmics reduced ventricular premature contractions by ≥50% in 55-62% of patients; combining disopyramide with mexiletine lowered side effects to 5% versus 13-22% with monotherapy.
Why the study?
Does single or combination therapy with class I antiarrhythmic agents reduce ventricular premature contractions in Japanese patients with ventricular arrhythmias?
Does single or combination therapy with class I antiarrhythmic agents reduce ventricular premature contractions in Japanese patients with ventricular arrhythmias?
Combination therapy with low-dose disopyramide and mexiletine provides similar efficacy for reducing ventricular premature contractions as single-agent therapy but with a lower incidence of side effects in Japanese patients.
No takes yet. Share an insight, caveat, or question.
Low-dose disopyramide-mexiletine combination was associated with fewer side effects for VPC suppression in Japanese patients; leaves open confirmation in randomized trials.
Tanabe et al. (1988) studied Ventricular arrhythmias (n=106). Class I antiarrhythmic agents (disopyramide, mexiletine, aprindine, cibenzoline) vs. Other class I antiarrhythmic agents or single vs combination therapy was evaluated on Fifty percent or more reduction in the frequency of ventricular premature contractions (VPCs). Class I antiarrhythmics reduced ventricular premature contractions by ≥50% in 55-62% of patients; combining disopyramide with mexiletine lowered side effects to 5% versus 13-22% with monotherapy.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: